Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19.

Literature DB >> 33394351

Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19.

Junsen Chen¹, Rui Huang¹, Yiwen Nie¹, Xinyue Wen¹, Ying Wu^2,3.

Abstract

Coronavirus disease 2019 (COVID-19), reminiscent of the severe acute respiratory syndrome (SARS) outbreak in 2003, has been a tragic disaster to people all over the world. As there is no specific drug for COVID-19, neutralizing antibodies are attracting more and more attention as one of the most effective means to combat the pandemic. Here, we introduced the etiological and serological characteristics of COVID-19, discussed the current stage of development of human monoclonal antibodies against SARS-CoV-2 and summarized the antigenic epitopes in the S glycoprotein, which may deepen the understanding of the profile of immune recognition and response against SARS-CoV-2 and provide insight for the design of effective vaccines and antibody-based therapies.

Entities: CellLine Chemical Disease Gene Mutation Species

Keywords: COVID-19; Epitopes; S glycoprotein; mAbs

Year: 2021 PMID： 33394351 DOI： 10.1007/s12250-020-00327-x

Source DB: PubMed Journal: Virol Sin ISSN： 1995-820X Impact factor: 4.327

45 in total

1. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.

Authors: Davide Corti; John Misasi; Sabue Mulangu; Daphne A Stanley; Masaru Kanekiyo; Suzanne Wollen; Aurélie Ploquin; Nicole A Doria-Rose; Ryan P Staupe; Michael Bailey; Wei Shi; Misook Choe; Hadar Marcus; Emily A Thompson; Alberto Cagigi; Chiara Silacci; Blanca Fernandez-Rodriguez; Laurent Perez; Federica Sallusto; Fabrizia Vanzetta; Gloria Agatic; Elisabetta Cameroni; Neville Kisalu; Ingelise Gordon; Julie E Ledgerwood; John R Mascola; Barney S Graham; Jean-Jacques Muyembe-Tamfun; John C Trefry; Antonio Lanzavecchia; Nancy J Sullivan
Journal: Science Date: 2016-02-25 Impact factor: 47.728

2. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.

Authors: Niveditha Devasenapathy; Zhikang Ye; Mark Loeb; Fang Fang; Borna Tadayon Najafabadi; Yingqi Xiao; Rachel Couban; Philippe Bégin; Gordon Guyatt
Journal: CMAJ Date: 2020-05-22 Impact factor: 8.262

Review 3. Deployment of convalescent plasma for the prevention and treatment of COVID-19.

Authors: Evan M Bloch; Shmuel Shoham; Arturo Casadevall; Bruce S Sachais; Beth Shaz; Jeffrey L Winters; Camille van Buskirk; Brenda J Grossman; Michael Joyner; Jeffrey P Henderson; Andrew Pekosz; Bryan Lau; Amy Wesolowski; Louis Katz; Hua Shan; Paul G Auwaerter; David Thomas; David J Sullivan; Nigel Paneth; Eric Gehrie; Steven Spitalnik; Eldad A Hod; Lewis Pollack; Wayne T Nicholson; Liise-Anne Pirofski; Jeffrey A Bailey; Aaron Ar Tobian
Journal: J Clin Invest Date: 2020-06-01 Impact factor: 14.808

Review 4. Coronaviruses: an overview of their replication and pathogenesis.

Authors: Anthony R Fehr; Stanley Perlman
Journal: Methods Mol Biol Date: 2015

5. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.

Authors: Xiangyang Chi; Renhong Yan; Jun Zhang; Guanying Zhang; Yuanyuan Zhang; Meng Hao; Zhe Zhang; Pengfei Fan; Yunzhu Dong; Yilong Yang; Zhengshan Chen; Yingying Guo; Jinlong Zhang; Yaning Li; Xiaohong Song; Yi Chen; Lu Xia; Ling Fu; Lihua Hou; Junjie Xu; Changming Yu; Jianmin Li; Qiang Zhou; Wei Chen
Journal: Science Date: 2020-06-22 Impact factor: 47.728

6. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2.

Authors: Danielle E Anderson; Chee Wah Tan; Wan Ni Chia; Barnaby E Young; Martin Linster; JennyG H Low; Yee-Joo Tan; Mark I-C Chen; Gavin J D Smith; Yee Sin Leo; David C Lye; Lin-Fa Wang
Journal: Emerg Microbes Infect Date: 2020-12 Impact factor: 7.163

7. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.

Authors: Yunlong Cao; Bin Su; Xianghua Guo; Wenjie Sun; Yongqiang Deng; Linlin Bao; Qinyu Zhu; Xu Zhang; Yinghui Zheng; Chenyang Geng; Xiaoran Chai; Runsheng He; Xiaofeng Li; Qi Lv; Hua Zhu; Wei Deng; Yanfeng Xu; Yanjun Wang; Luxin Qiao; Yafang Tan; Liyang Song; Guopeng Wang; Xiaoxia Du; Ning Gao; Jiangning Liu; Junyu Xiao; Xiao-Dong Su; Zongmin Du; Yingmei Feng; Chuan Qin; Chengfeng Qin; Ronghua Jin; X Sunney Xie
Journal: Cell Date: 2020-05-18 Impact factor: 41.582

8. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.

Authors: Jasper Fuk-Woo Chan; Kin-Hang Kok; Zheng Zhu; Hin Chu; Kelvin Kai-Wang To; Shuofeng Yuan; Kwok-Yung Yuen
Journal: Emerg Microbes Infect Date: 2020-01-28 Impact factor: 7.163

9. Development of an inactivated vaccine candidate for SARS-CoV-2.

Authors: Qiang Gao; Linlin Bao; Haiyan Mao; Lin Wang; Kangwei Xu; Minnan Yang; Yajing Li; Ling Zhu; Nan Wang; Zhe Lv; Hong Gao; Xiaoqin Ge; Biao Kan; Yaling Hu; Jiangning Liu; Fang Cai; Deyu Jiang; Yanhui Yin; Chengfeng Qin; Jing Li; Xuejie Gong; Xiuyu Lou; Wen Shi; Dongdong Wu; Hengming Zhang; Lang Zhu; Wei Deng; Yurong Li; Jinxing Lu; Changgui Li; Xiangxi Wang; Weidong Yin; Yanjun Zhang; Chuan Qin
Journal: Science Date: 2020-05-06 Impact factor: 47.728

Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19.

1. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.

2. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.

Review 3. Deployment of convalescent plasma for the prevention and treatment of COVID-19.

Review 4. Coronaviruses: an overview of their replication and pathogenesis.

5. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.

6. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2.

7. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.

8. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.

9. Development of an inactivated vaccine candidate for SARS-CoV-2.

10. SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate.

1. A small interfering RNA (siRNA) database for SARS-CoV-2.

Review 2. Insights into the evolutionary and prophylactic analysis of SARS-CoV-2: A review.

Review 3. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice.

Review 4. Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection.